Design Therapeutics (DSGN) Projected to Post Earnings on Monday

Key Points

• Design Therapeutics is projected to announce its Q1 2025 earnings on August 4th, with analysts forecasting a loss of ($0.32) per share.
• The company recently reported a loss of ($0.31) per share for its previous quarter, which was lower than the expected ($0.28).
• Design Therapeutics shares opened at $4.02 and have a market cap of $228.22 million, with 56.64% of the stock held by institutional investors.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Monday, August 4th. Analysts expect Design Therapeutics to post earnings of ($0.32) per share for the quarter.

Design Therapeutics (NASDAQ:DSGN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.03). On average, analysts expect Design Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Design Therapeutics Stock Down 5.7%

Shares of Design Therapeutics stock traded down $0.23 during trading on Thursday, reaching $3.80. The company's stock had a trading volume of 115,447 shares, compared to its average volume of 131,888. Design Therapeutics has a 12-month low of $2.60 and a 12-month high of $7.77. The company has a market capitalization of $215.73 million, a P/E ratio of -3.83 and a beta of 1.56. The business has a 50 day moving average price of $3.90 and a 200-day moving average price of $4.11.

Institutional Trading of Design Therapeutics

Institutional investors have recently bought and sold shares of the company. Woodline Partners LP purchased a new stake in Design Therapeutics during the first quarter worth $2,492,000. Strs Ohio purchased a new stake in Design Therapeutics during the first quarter worth $87,000. Finally, Jane Street Group LLC purchased a new stake in Design Therapeutics during the first quarter worth $70,000. 56.64% of the stock is currently owned by hedge funds and other institutional investors.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.